Profile Details

Contact

★★★★★

☆☆☆☆☆

USD 80 /hr

★★★★★

☆☆☆☆☆

Hire Dr. Jonathan W.

United Kingdom

USD 80 /hr

Biologist BSc MSc PhD

Profile Summary

My research experience began during my BSc where I did a year’s sabbatical in the Endocrinology department at St Thomas hospital. I then went on to do an MSc in Bioinformatics to ensure that I had fundamental knowledge as to the power and advantages of numerous scientific tools used regularly by scientists such as sequence analysis. I did my PhD at the Institute of Cellular and Molecular Sciences (ICMS) at Barts and the London, Queen Mary's School of Medicine and Dentistry where I investigated the regulation of epidermal lipogenesis by the enzymes sterol regulatory element binding proteins 1 and 2 (SREBP). My broad field of interest is Biology and Cancer Therapeutics. During my first post-doc, at the ICR, I was focused on understanding mechanisms that determine response and resistance to anti-angiogenic therapy. My second post-doc was focused on metabolism in angiogenesis. During my post-doctoral positions I have, along with my supervisors, peer reviewed research articles for academic journals including Cancer Research, Nature and Cell along with co-reviewing grant applications. I have also obtained my own funding including a Marie Curie intra-European fellowship. My current position is at the ICR as a Senior Scientific Officer working on Prostate Cancer and Next Generation Sequencing. When not in the laboratory, I am mostly focussing on writing research articles, putting together grant proposals and peer reviewing submitted articles. In depth knowledge of the following assays: Molecular biology: RT-PCR, qPCR, ddPCR, primer design, molecular cloning, transformation of competent bacteria, extraction and purification of DNA and RNA (from varying materials including CTCs and FFPE samples), DNA comet assay, DNA sequencing, RNA sequencing. Biochemistry: radioimmunoassay, HPLC, western blotting, immunoprecipitation, ELISA, immunohistochemistry, immunofluorescence, whole mount in situ hybridization, metabolic flux assays. Cellular biology: culture of primary human cells and cancer cell lines, immunocytochemistry, confocal microscopy, flow cytometry, cell proliferation and migration assays, transfection/ transduction of cells, CTC isolation. Model systems: in vitro angiogenesis assays (e.g. aortic ring assay, retina vascularity assay, endothelial tube formation assays), epidermal organotypic culture, embryonic skin explant culture, mouse subcutaneous tumour models, transgenic mouse models, patient derived organoid models, patient derived xenograft models.

Subject Matter Expertise

• ☆ Molecular Engineering
• ☆ Molecular Modeling
• ☆ Separation & Purification
• ☆ Molecular Imaging
• ☆ Liquid Chromatography/HPLC
• ☆ Biology/Life Sciences
• ☆ Developmental Biology
• ☆ Microbiology
• ☆ Biochemistry
• ☆ Biochemical Assays
• ☆ Molecular Biology
• ☆ Genetics
• ☆ Molecular Evolution
• ☆ PCR
• ☆ Next Generation Sequencing (NGS)
• ☆ DNA Sequencing
• ☆ RNA Sequencing
• ☆ Cell Signaling Pathways
• ☆ Biotechnology & Bioengineering
• ☆ Bioinformatics
• ☆ Cell Banking
• ☆ Protein/Enzyme Engineering
• ☆ Blotting
• ☆ Immunohistochemistry
• ☆ Cytometry
• ☆ Dentistry
• ☆ Medical Sciences
• ☆ Cancer Research

Services

• Writing
• Research
• Consulting
• Data & AI
• Product Development

Work Experience

Senior Scientific Officer

Institute of Cancer Research Sutton

2013 - Present

Post-doctoral researcher

VIB Vesalius Research Center

2012 - 2013

Post-doctoral researcher

Institute of Cancer Research

2008 - 2011

Education

Education details not provided.

Certifications

• Certification details not provided.

Publications

JOURNAL ARTICLE

(2017). Novel Junction-specific and Quantifiable In Situ Detection of AR-V7 and its Clinical Correlates in Metastatic Castration-resistant Prostate Cancer . European urology.

(2016). Analytical Validation and Clinical Qualification of a New Immunohistochemical Assay for Androgen Receptor Splice Variant-7 Protein Expression in Metastatic Castration-resistant Prostate Cancer . European urology.

(2016). Targeting Androgen Receptor Aberrations in Castration-Resistant Prostate Cancer . Clinical cancer research : an official journal of the American Association for Cancer Research.

(2016). Preclinical Evidence That Trametinib Enhances the Response to Antiangiogenic Tyrosine Kinase Inhibitors in Renal Cell Carcinoma . Molecular cancer therapeutics.

(2015). Targeting the androgen receptor pathway in castration-resistant prostate cancer: progresses and prospects . Oncogene.

(2013). Control of vessel sprouting by genetic and metabolic determinants . Trends in endocrinology and metabolism: TEM.

(2013). Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer . The Journal of clinical investigation.

(2012). Contrasting effects of sunitinib within in vivo models of metastasis . Angiogenesis.

(2011). FGFR signaling promotes the growth of triple-negative and basal-like breast cancer cell lines both in vitro and in vivo . Clinical cancer research : an official journal of the American Association for Cancer Research.

(2011). Fibroblast growth factor 2 regulates endothelial cell sensitivity to sunitinib . Oncogene.

(2010). Whole-mount assays for gene induction and barrier formation in the developing epidermis . Methods in molecular biology (Clifton, N.J.).

(2009). Akt-dependent Pp2a activity is required for epidermal barrier formation during late embryonic development . Development (Cambridge, England).

(2009). Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors . Nature medicine.

(2007). AKT-dependent HspB1 (Hsp27) activity in epidermal differentiation . The Journal of biological chemistry.